CIK 0001534969
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
SERA PROGNOSTICS, INC.
Sign in to watch- Ticker
- SERA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 261911522
- Phone
- +1 801-990-0520
- Business address
- 2749 E. PARLEYS WAY, SUITE 200, SALT LAKE CITY, UT, 84109
- Former names
- SERA PROGNOSTICS, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,563
- in 6 filings
Net −$79,563. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-07-27 | Boniface John J. Chief Scientific Officer | Sale | −1,000 | $2.22 | $2K | 46,510 |
| 2022-07-27 | Boniface John J. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −1,000 | 844 | ||
| 2022-07-26 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $2.15 | $6K | 46,510 |
| 2022-07-19 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.86 | $5K | 49,235 |
| 2022-07-18 | Blue Ox Healthcare Partners, LLC 10% owner | Other disposition | −1,383,094 | 132,501 | ||
| 2022-07-18 | Blue Ox Healthcare Partners, LLC 10% owner | Other disposition | −997,627 | 77,420 | ||
| 2022-07-18 | Blue Ox Healthcare Partners, LLC 10% owner | Other disposition | −1,157,764 | 46,744 | ||
| 2022-07-12 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.84 | $5K | 51,960 |
| 2022-07-05 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.63 | $4K | 54,685 |
| 2022-06-29 | Boniface John J. Chief Scientific Officer | Exercise or conversion | +1,000 | $0.73 | $730 | 58,410 |
| 2022-06-29 | Boniface John J. Chief Scientific Officer | Sale | −1,000 | $1.72 | $2K | 57,410 |
| 2022-06-29 | Boniface John J. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −1,000 | 1,844 | ||
| 2022-06-28 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.89 | $5K | 57,410 |
| 2022-06-21 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.31 | $4K | 60,135 |
| 2022-06-14 | Jackson Benjamin General Counsel | Purchase | +8,000 | $1.20 | $10K | 8,000 |
| 2022-06-14 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.21 | $3K | 62,860 |
| 2022-06-07 | Boniface John J. Chief Scientific Officer | Sale | −2,725 | $1.30 | $4K | 65,585 |
| 2022-06-03 | Lawrence Sandra AJ Director | Grant or award · Stock Option (right to buy) | +149,675 | 149,675 | ||
| 2022-06-03 | Trimble Ryan Director | Grant or award · Stock Option (right to buy) | +149,675 | 149,675 | ||
| 2022-06-03 | Lindgardt Zhenya Director | Grant or award · Stock Option (right to buy) | +149,675 | 149,675 |
Page 18 of 23 · 457 trades